BridgeBio's Phase 3 win for rare disease drug Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 27 October, 2025

Start your year where biopharma sets its agenda. Join Endpoints News and industry leaders in San Francisco as we unpack the forces shaping dealmaking, China's emerging role and regulatory shifts. Save $200 with Early Bird rates — reserve your spot today.

presented by Gene Ther­a­py for the Mass­es: Ex­pand­ing the Treat­ment Par­a­digm with HCAd

news Novartis to buy RNA drugmaker Avidity Biosciences for $12B Hemab nabs $157M to finance the 'ultimate coagulation disorder' biotech BridgeBio shifts filing plans for rare disease drug after Phase 3 success Novo ended Akero deal talks before returning for $4.7B MASH acquisition Neumora moves forward with NLRP3 in obesity after Ventyx's drug failed to deliver weight loss Bayer gets FDA approval for hot flash treatment

Nov 13 11:00am ET Driving down the cost: Optimising CGT with the right CDMO partner sponsored by OXB

Biopharma is entering a new era of AI-driven discovery and precision medicine — but growth is challenged by regulatory shifts and global uncertainty. Join us in London to hear from the leaders shaping what’s next.

endpoints pharma Halda's first clinical test of RIPTAC drugs suggests a safer way to kill cancer FDA inspection turns up lizards, cats at unauthorized Indian drug and API warehouse Philly is on Lilly's radar for next Gateway Labs site Eli Lilly to seek Olumiant approval in adolescents with alopecia Inhibrx will head to FDA for bone cancer drug next year after strong data

in case you missed it 1. Lilly expands gene therapy work with Adverum acquisition 2. Biogen pays $70M upfront for preclinical drug with same target from HI-Bio acquisition 3. Zai Lab shares Phase 1 data for lung cancer drug that could spar with Amgen’s Imdelltra 4. Merus makes push into colorectal cancer with early positive data 5. Peer Review Novo Nordisk lines up corporate affairs exec, overshadowed by board drama 6. Remix Therapeutics reveals first signs of tumor shrinkage with its small molecule mRNA degrader 7. News Briefing FDA rejects Sydnexis’ myopia drug for kids; Chugai to buy Renalys for $98M upfront 8.